Brief: Intelgenx Says Got Clarity From FDA On CMC Information Required For Resubmission Of NDA For Acute Migraines Treatment
11/06/2020 13:30
June 11 (Reuters) - Intelgenx Technologies Corp IGX.V :
* INTELGENX PROVIDES UPDATE ON RIZAPORT® VERSAFILM® NDA
RESUBMISSION PROCESS FOLLOWING TYPE A MEETING WITH THE FDA
* INTELGENX TECHNOLOGIES CORP - OBTAINED CLARITY FROM FDA
ON CMC
INFORMATION REQUIRED FOR RESUBMISSION OF NDA FOR ACUTE MIGRAINES
TREATMENT
Source text for Eikon: ID:nGNX2RJVPs
Further company coverage: IGX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelgenx Technologies
See all newsBrief: Intelgenx Obtains Court-Approval Of Sale & Investment Solicitation Process
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA